BioKangtai(SZ:300601) Hua Xia Shi Bao·2025-09-23 08:46Core Viewpoint - The company, Kangtai Biological, is facing its most challenging period since its listing, with significant declines in net profit and profitability despite a revenue increase [2][3]. Financial Performance - In the first half of 2025, Kangtai Biological reported total revenue of 1.392 billion yuan, a year-on-year increase of 15.81% [3]. - The net profit attributable to shareholders was only 37.53 million yuan, a dramatic decline of 77.30% compared to the previous year [3]. - The company's non-recurring net profit was 18 million yuan, down 84.85% year-on-year [2][3]. - The gross profit margin decreased by 7.83 percentage points to 75.95%, while the net profit margin fell from 13.76% to 2.70% [3]. - This performance marks the lowest half-year net profit since the company went public [3]. Stock Performance - As of September 19, 2025, Kangtai Biological's stock price plummeted nearly 90% from 149.64 yuan per share on August 4, 2020, to 17.17 yuan per share [5]. - Despite a general rise in the pharmaceutical industry, Kangtai's stock price only increased by 0.74% from the beginning of the year to September 20, while the Wind Pharmaceutical Index rose by 31.5% [5]. Market Challenges - The company faces multiple challenges, including market saturation and intensified competition for its core products, which hinder market share growth [7]. - Operational inefficiencies, such as suboptimal production processes and poor cost control, are impacting profitability and operational efficiency [8]. - Strategic misalignments in market positioning and product development may have prevented the company from adapting to market changes [8]. Industry Factors - The decline in birth rates has significantly affected the vaccine market, reducing the potential vaccination population [9]. - The waning demand for COVID-19 vaccines has led to excess production capacity and declining performance for many vaccine companies, including Kangtai [9]. - Price reduction policies in the industry have compressed profit margins, making it increasingly difficult for companies to maintain profitability [9]. Product Performance - Kangtai's first-class vaccines (immunization planning vaccines) saw a revenue increase of 92% to 51.65 million yuan, but the gross margin plummeted by 37.5 percentage points to -5.01% [11]. - The decline in profitability for first-class vaccines is attributed to price reductions from centralized procurement policies and rising production costs [11][12]. - The second-class vaccines (non-immunization planning vaccines) experienced a revenue increase of 1.3 billion yuan, but the gross margin fell by 5.48 percentage points to 80.32%, indicating a "revenue increase without profit increase" scenario [15]. Competitive Landscape - The market for the 13-valent pneumonia vaccine has become highly competitive, with Kangtai's sales volume declining by 44.31% in the first half of 2025 [17]. - The company faces challenges from new entrants and established competitors, which have intensified price competition [18].